Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M171,682Revenue $M42,237Net Margin (%)27.0Z-Score3.9
Enterprise Value $M177,510EPS $4.1Operating Margin %12.5F-Score5
P/E(ttm))14.7Cash Flow Per Share $6.3Pre-tax Margin (%)40.0Higher ROA y-yY
Price/Book3.510-y EBITDA Growth Rate %5.4Quick Ratio1.5Cash flow > EarningsN
Price/Sales4.25-y EBITDA Growth Rate %4.0Current Ratio1.8Lower Leverage y-yY
Price/Cash Flow7.1y-y EBITDA Growth Rate %90.6ROA % (ttm)13.1Higher Current Ratio y-yN
Dividend Yield %2.9Insider Buy (3m)0ROE % (ttm)27.7Less Shares Outstanding y-yY
Payout Ratio %43.0Shares Outstanding M2,838ROI % (ttm)6.0Gross Margin Increase y-yN

Gurus Latest Trades with MRK

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MRKVanguard Health Care Fund 2015-03-31 Add0.53%$56.06 - $63.03
($59.34)
$ 60.492%Add 12.04%40,096,948
MRKMario Gabelli 2015-03-31 Add0.01%$56.06 - $63.03
($59.34)
$ 60.492%Add 11.45%160,943
MRKKen Fisher 2015-03-31 Add$56.06 - $63.03
($59.34)
$ 60.492%Add 0.59%6,679,499
MRKIrving Kahn 2014-12-31 Reduce-0.54%$53.43 - $61.88
($58.42)
$ 60.493%Reduce -5.08%1,052,807
MRKVanguard Health Care Fund 2014-12-31 Add0.32%$53.43 - $61.88
($58.42)
$ 60.493%Add 7.08%35,788,048
MRKJoel Greenblatt 2014-12-31 Add0.23%$53.43 - $61.88
($58.42)
$ 60.493%Add 94.88%1,045,652
MRKJean-Marie Eveillard 2014-12-31 Reduce-0.16%$53.43 - $61.88
($58.42)
$ 60.493%Reduce -99.16%9,050
MRKJoel Greenblatt 2014-09-30 Add0.24%$55.64 - $61.18
($58.89)
$ 60.493%Add 323.00%536,550
MRKJean-Marie Eveillard 2014-09-30 Reduce-0.1%$55.64 - $61.18
($58.89)
$ 60.493%Reduce -38.25%1,083,826
MRKIrving Kahn 2014-09-30 Reduce-0.09%$55.64 - $61.18
($58.85)
$ 60.493%Reduce -0.97%1,109,189
MRKCharles Brandes 2014-09-30 Reduce-0.08%$55.64 - $61.18
($58.85)
$ 60.493%Reduce -4.69%2,320,288
MRKVanguard Health Care Fund 2014-09-30 Reduce-0.07%$55.64 - $61.18
($58.85)
$ 60.493%Reduce -1.38%33,420,748
MRKRobert Bruce 2014-09-30 Add0.06%$55.64 - $61.18
($58.85)
$ 60.493%Add 1.34%265,000
MRKDodge & Cox 2014-09-30 Reduce-0.05%$55.64 - $61.18
($58.85)
$ 60.493%Reduce -2.51%35,057,668
MRKGeorge Soros 2014-09-30 Sold Out -0.04%$55.64 - $61.18
($58.89)
$ 60.493%Sold Out0
MRKKen Fisher 2014-09-30 Add0.01%$55.64 - $61.18
($58.85)
$ 60.493%Add 1.07%6,533,475
MRKNWQ Managers 2014-09-30 Reduce$55.64 - $61.18
($58.85)
$ 60.493%Reduce -0.59%83,811
MRKRuane Cunniff 2014-09-30 Add$55.64 - $61.18
($58.85)
$ 60.493%Add 3.80%4,784
MRKJames Barrow 2014-09-30 Reduce$55.64 - $61.18
($58.85)
$ 60.493%Reduce -0.11%22,769,088
MRKMario Gabelli 2014-09-30 Add$55.64 - $61.18
($58.85)
$ 60.493%Add 1.49%162,706
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MRK is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


MRK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Kuhlik Bruce NExe V-P & Gen Counsel 2015-04-29Sell156,902$59.820.07view
Holston Michael JEVP, Legal 2015-04-29Sell95,624$59.840.03view
FRAZIER KENNETH CChairman, President & CEO 2015-02-18Sell5,164$58.672.03view
Deese Willie AExe V-P & Pres. MMD 2015-02-11Sell135,864$58.562.22view
WENDELL PETER CDirector 2015-02-09Sell5,000$58.761.87view
Schechter Adam HEVP & Pres-Global Human Health 2015-01-15Sell74,200$62.48-4.19view
FRAZIER KENNETH CChairman, President & CEO 2015-01-09Sell8,840$62.47-4.18view
FRAZIER KENNETH CChairman, President & CEO 2014-12-10Sell9,846$60-0.23view
Kuhlik Bruce NExe V-P & Gen Counsel 2014-12-08Sell50,000$62-3.45view
LAZARUS ROCHELLE BDirector 2014-11-26Sell10,000$59.630.39view

Press Releases about MRK :

    Quarterly/Annual Reports about MRK:

      News about MRK:

      Articles On GuruFocus.com
      Biogen Making A Breakthrough In Treating Alzheimer’s May 02 2015 
      Robert Bruce's Top Growth Stocks Apr 13 2015 
      Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
      Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 
      Johnson & Johnson Unfazed By $25 Million Fine Mar 13 2015 
      Bayer Goes Into Disinvestment Mode Due To Falling Profit Numbers Feb 27 2015 
      Abner Herrman's Top Three Holdings Feb 26 2015 
      PRIMECAP Management's New Positions Feb 13 2015 
      The Dogs of the Dow Get Off to a Sluggish Start in 2015 Feb 11 2015 
      Gilead Sciences Falls 10% After More Than Doubling Drug Discounts For 2015 Feb 05 2015 

      More From Other Websites
      A tale of two Mercks: Confusion mounts over shared brand name May 03 2015
      The Advantages of Owning Individual Stocks May 03 2015
      Top picks in health care May 01 2015
      Gilead Soothes Price War Worry With Q1 Results May 01 2015
      Bank Of America Reviews Gilead Earnings May 01 2015
      Merck deal boosts sales but not income at Bayer Apr 30 2015
      Is a choice between Apple and Merck stock that obvious? Apr 30 2015
      Rubella Eliminated From The Americas, Thanks To MMR Vaccine Apr 30 2015
      Paul T. Anastas Awarded Emanuel Merck Lectureship 2015 Apr 30 2015
      Bayer First-Quarter Profit Rises on Xarelto, Merck Acquisition Apr 30 2015
      Merck & Co. (MRK) Earnings Analysis: By the Numbers Apr 29 2015
      Pfizer (PFE) Earnings Analysis: By the Numbers Apr 29 2015
      Januvia Passes, Afrezza On Deck Apr 29 2015
      Bristol-Myers Squibb (BMY) Earnings Analysis: By the Numbers Apr 29 2015
      EU Needs New Drugs to Fight Antibiotic Resistance Apr 29 2015
      What's Wall Street Been Saying About Gilead Lately? Apr 29 2015
      April US Consumer Confidence Dips to 95.2 on Rising Fuel Costs Apr 29 2015
      This Pharma Firm Passes the Test Apr 29 2015
      Investors on Fed statement, first-quarter GDP watch Apr 29 2015
      Pfizer, Merck and Bristol-Myers Squibb Report Solid Results Apr 28 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      FEEDBACK